Bristol-Myers Squibb Company
METHODS OF TREATMENT USING IL-23p19 MONOCLONAL ANTIBODIES
Last updated:
Abstract:
The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
Status:
Application
Type:
Utility
Filling date:
10 Jun 2019
Issue date:
6 Feb 2020